Fresenius Medical Care Annual General Meeting: Company Makes Significant Progress in Its Transformation Efforts and Confirms Its Ambitious 2024 Growth Targets
Fresenius Medical Care Annual General Meeting: Company Makes Significant Progress in Its Transformation Efforts and Confirms Its Ambitious 2024 Growth Targets
- Today's Annual General Meeting was the first one following the change in legal form completed in November 2023
- Shareholders voted in favor of the proposed dividend of 1.19 euros, representing an increase of around 6 percent compared to the previous year
- New compensation system for Management Board approved
- Ambitious growth targets for 2024 confirmed
- 今天的年度股東大會是繼2023年11月完成法律形式變更後的第一次年度股東大會
- 股東投票贊成1.19歐元的擬議股息，與去年相比增長了約6％
- 管理委員會的新薪酬制度獲得批准
- 2024年雄心勃勃的增長目標得到確認
BAD HOMBURG, Germany, May 16, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the global leader in providing products and services for people with kidney diseases, is executing its strategic turnaround plan and is well on track to achieve its goals for 2024.
德國巴特洪堡，2024年5月16日 /PRNewswire/ — 爲腎臟疾病患者提供產品和服務的全球領導者費森尤斯醫療（FME）正在執行其戰略週轉計劃，並有望實現其2024年的目標。
At today's Annual General Meeting, Michael Sen, Chairman of the Supervisory Board of Fresenius Medical Care AG, said: "Fresenius Medical Care has made significant progress in 2023. The consistent implementation of the transformation program is beginning to pay off. The deconsolidation and the independence are providing Fresenius Medical Care with everything it needs to further strengthen its position in the dialysis market and to realize its full potential."
在今天的年度股東大會上， 邁克爾·森，費森尤斯醫療股份公司監事會主席表示：“費森尤斯醫療在2023年取得了重大進展。持續實施轉型計劃已開始獲得回報。解散和獨立性爲費森尤斯醫療提供了進一步鞏固其在透析市場的地位並充分發揮其潛力所需的一切。”
Michael Sen added: "On behalf of the Supervisory Board, I would like to thank the members of the Management Board under the leadership of CEO Helen Giza for their trusting cooperation and very good performance in the past financial year. The newly composed management team has the necessary expertise, energy, and experience to take the company forward in the interests of patients, employees, and shareholders."
邁克爾·森補充說：“我謹代表監事會感謝首席執行官海倫·吉薩領導下的管理委員會成員在過去一個財政年度的信任合作和出色的表現。新組建的管理團隊擁有必要的專業知識、精力和經驗，可以推動公司向前發展，以維護患者、員工和股東的利益。”
Helen Giza, CEO of Fresenius Medical Care AG, said: "For 2023, we delivered top- and bottom-line growth, and exceeded our operating income outlook that we raised twice. Our FME25 transformation program is ahead of schedule and our portfolio optimization program is well underway. All our achievements mark a highly successful conclusion to an exceptional year of transformation and turnaround efforts."
海倫吉薩費森尤斯醫療股份公司首席執行官表示：“2023年，我們實現了收入和利潤增長，並超過了我們兩次上調的營業收入前景。我們的 FME25 轉型計劃已提前完成，我們的投資組合優化計劃正在順利進行中。我們的所有成就都標誌着這一非凡的轉型和轉型努力的圓滿結束。”
"Turning to 2024, this year is being spent in singular focus on disciplined execution and value creation. While 2023 was a year of level-setting, 2024 is one of momentum-building," said Giza. The CEO thanked employees for their dedication and commitment to ensuring high-quality care for patients worldwide.
“展望2024年，今年將重點放在紀律執行和價值創造上。雖然2023年是設定水平的一年，但2024年是勢頭增強的一年，” 吉薩說。首席執行官感謝員工爲確保爲全球患者提供高質量護理所做的奉獻和承諾。
A significant majority of 96.97 percent of shareholders approved the dividend proposal for fiscal year 2023 of 1.19 euros, representing an increase of around 6 percent compared to the previous year (2022: 1.12 euros). The proposal aligns with the dividend policy of the company to adjust payouts according to Group net income development (excluding special items).
96.97％的股東中的絕大多數批准了2023財年1.19歐元的股息提案，與上一年（2022年：1.12歐元）相比增長了約6％。該提案符合公司的股息政策，即根據集團淨收入的發展（不包括特殊項目）調整派息。
The shareholders also approved, with a majority of 87.58 percent, the new Management Board's compensation system.
股東們還以87.58％的多數批准了新管理委員會的薪酬制度。
With a majority of 99.49 percent, the shareholders also approved the update to the Supervisory Board's remuneration.
股東們還以99.49％的多數票批准了監事會薪酬的更新。
The Management Board and the Supervisory Board were discharged for the year 2023 with majorities of 98.71 percent and 98.42 percent, respectively.
管理委員會和監事會在2023年解散了大多數，分別爲98.71％和98.42％。
At the Annual General Meeting, 88.39 percent of the share capital was represented.
在年度股東大會上，88.39％的股本派代表出席。
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for people with kidney diseases, of whom approximately 4.1 million patients worldwide receive regular dialysis treatment. Through its network of 3,862 dialysis centers, Fresenius Medical Care provides dialysis treatment for approximately 325,000 patients worldwide and is the leading provider of dialysis products such as dialysis machines and dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and the New York Stock Exchange (FMS).
關於費森尤斯醫療：
費森尤斯醫療是全球領先的腎臟疾病患者產品和服務提供商，其中全球約有410萬患者接受定期透析治療。費森尤斯醫療通過其由3,862個透析中心組成的網絡，爲全球約32.5萬名患者提供透析治療，並且是透析機和透析器等透析產品的領先供應商。費森尤斯醫療在法蘭克福證券交易所（FME）和紐約證券交易所（FMS）上市。
For further information, please visit .
欲了解更多信息，請訪問。
Legal Disclaimer:
This communication contains forward-looking statements, which are subject to various risks and uncertainties. Future results may differ significantly from the currently expected results due to various factors such as changes in the business, economic, and competitive situation, changes in laws, regulatory approvals, the impact of the Covid-19 pandemic, results of clinical studies, exchange rate fluctuations, uncertainties regarding litigation or investigative proceedings, and the availability of financial resources. These and other risks and uncertainties are described in detail in the reports of Fresenius Medical Care AG filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG assumes no obligation to update the forward-looking statements contained in this communication.
法律免責聲明：
本通訊包含前瞻性陳述，這些陳述受各種風險和不確定性的影響。由於各種因素，例如業務、經濟和競爭形勢的變化、法律的變化、監管部門的批准、Covid-19疫情的影響、臨床研究的結果、匯率波動、訴訟或調查程序的不確定性以及財務資源的可用性，未來的結果可能與當前的預期結果有很大差異。費森尤斯醫療股份公司向美國證券交易委員會提交的報告詳細描述了這些風險和其他風險和不確定性。費森尤斯醫療股份公司沒有義務更新本通訊中包含的前瞻性陳述。
Media Contact
Christine Peters
T +49 160 60 66 770
[email protected]
媒體聯繫人
克里斯汀·彼得斯
電話 +49 160 60 66 770
[電子郵件保護]
Contact for Analysts and Investors
Dr. Dominik Heger
T +49 6172 609 2601
[email protected]
分析師和投資者聯繫方式
多米尼克·黑格博士
電話 +49 6172 609 2601
[電子郵件保護]
SOURCE Fresenius Medical Care Holdings, Inc.
來源 Fresenius Medical Care Holdings, Inc.
譯文內容由第三人軟體翻譯。